Marginal zone lymphoma(MZL) is incurable, the vast majority of MZL patients eventually will face disease relapsing or progression .~There is no standard second-line treatment for relapsed/refractory MZL, and the synergistic effect of obintuzumab and lenalidomide had been verified in other indolent lymphomas.~This trial is designed to investigate the efficacy and safety of the combination of obintuimab(GA101) and lenalidomide(GL therapy) in R/R marginal zone lymphoma, in order to find a safe and effective option in this type of disease.
This is a prospective, multi-center clinical study to enroll 59 patients with relapsed and refractory MZL. The study was designed to assess the efficacy and safety of the combination of obintuzumab and lenalidomide in the treatment of relapsed and refractory(R/R) marginal zone lymphoma (MZL).